$20,000 of PTC THERAPEUTICS lobbying was just disclosed, from Q1 of 2025, in a new Lobbying Disclosure Act filing.
This included lobbying on issues like:
"Seeking drug approval through the FDA."
You can find more data on corporate lobbying on Quiver Quantitative.
PTCT Insider Trading Activity
PTCT insiders have traded $PTCT stock on the open market 69 times in the past 6 months. Of those trades, 0 have been purchases and 69 have been sales.
Here’s a breakdown of recent trading of $PTCT stock by insiders over the last 6 months:
- MARK ELLIOTT BOULDING (EXEC. VP AND CLO) has made 0 purchases and 19 sales selling 193,337 shares for an estimated $10,159,420.
- NEIL GREGORY ALMSTEAD (CHIEF TECHNICAL OPS OFFICER) has made 0 purchases and 14 sales selling 77,535 shares for an estimated $4,009,259.
- JEROME B ZELDIS has made 0 purchases and 5 sales selling 24,000 shares for an estimated $1,235,897.
- CHRISTINE MARIE UTTER (SVP, CHIEF ACCOUNTING OFFICER) has made 0 purchases and 8 sales selling 22,510 shares for an estimated $1,142,121.
- MATTHEW B. KLEIN (CHIEF EXECUTIVE OFFICER) has made 0 purchases and 5 sales selling 20,615 shares for an estimated $968,344.
- ERIC PAUWELS (CHIEF BUSINESS OFFICER) has made 0 purchases and 9 sales selling 17,900 shares for an estimated $945,231.
- STEPHANIE OKEY sold 5,000 shares for an estimated $270,000
- LEE SCOTT GOLDEN (EVP & CHIEF MEDICAL OFFICER) has made 0 purchases and 5 sales selling 4,662 shares for an estimated $220,196.
- PIERRE GRAVIER (CHIEF FINANCIAL OFFICER) has made 0 purchases and 2 sales selling 2,335 shares for an estimated $117,006.
- ALLAN STEVEN JACOBSON sold 1,230 shares for an estimated $63,369
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
PTCT Hedge Fund Activity
We have seen 126 institutional investors add shares of PTCT stock to their portfolio, and 91 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- TORONTO DOMINION BANK added 3,286,729 shares (+inf%) to their portfolio in Q4 2024, for an estimated $148,362,947
- WELLINGTON MANAGEMENT GROUP LLP removed 3,105,676 shares (-39.3%) from their portfolio in Q4 2024, for an estimated $140,190,214
- DRIEHAUS CAPITAL MANAGEMENT LLC added 1,041,059 shares (+inf%) to their portfolio in Q4 2024, for an estimated $46,993,403
- UBS GROUP AG added 905,980 shares (+548.8%) to their portfolio in Q4 2024, for an estimated $40,895,937
- POINT72 ASSET MANAGEMENT, L.P. added 867,502 shares (+150.6%) to their portfolio in Q4 2024, for an estimated $39,159,040
- ARMISTICE CAPITAL, LLC removed 856,898 shares (-11.8%) from their portfolio in Q4 2024, for an estimated $38,680,375
- JACOBS LEVY EQUITY MANAGEMENT, INC removed 659,778 shares (-44.4%) from their portfolio in Q4 2024, for an estimated $29,782,378
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
PTCT Analyst Ratings
Wall Street analysts have issued reports on $PTCT in the last several months. We have seen 2 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Cantor Fitzgerald issued a "Overweight" rating on 02/03/2025
- RBC Capital issued a "Outperform" rating on 01/07/2025
To track analyst ratings and price targets for PTCT, check out Quiver Quantitative's $PTCT forecast page.
PTCT Price Targets
Multiple analysts have issued price targets for $PTCT recently. We have seen 2 analysts offer price targets for $PTCT in the last 6 months, with a median target of $55.0.
Here are some recent targets:
- Brian Abrahams from RBC Capital set a target price of $58.0 on 01/07/2025
- Joel Beatty from Robert W. Baird set a target price of $52.0 on 11/27/2024
This article is not financial advice. See Quiver Quantitative's disclaimers for more information.
